In this interactive, CME/CE/CPE-certified video module, Jonathan Scott Coblyn, MD; Jessica Farrell, PharmD; and Frances Griffin, RN, BSN, provide multidisciplinary perspectives on best practices in the use of traditional, biologic, and targeted synthetic DMARD monotherapy to treat rheumatoid arthritis.
In this downloadable slideset, Jonathan Scott Coblyn, MD; Jessica Farrell, PharmD; and Frances Griffin, RN, BSN, provide an overview of best practices in the use of monotherapy to treat rheumatoid arthritis.
Here’s my take on the patients who are best suited to receive biologic or targeted synthetic DMARD monotherapy.
What are the data supporting the use of newer agents as monotherapy for patients with RA? Here’s my take.
Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112
Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.